Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FRRM9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,598
Award facts
- Contract value 100% obligated
- $20,598.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,598.16 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. The award, issued on January 20, 2026, with an ultimate completion date of February 10, 2026, utilizes no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. This delivery order falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded in November 2025 that positions the company as a critical regional pharmaceutical supplier for Department of Defense medical operations.
DMS Pharmaceutical Group specializes in distributing comprehensive pharmaceutical products and medical consumables to federal agencies, with a product portfolio encompassing branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The PPV-G GEN V program, part of the broader $30.3 billion acquisition strategy, enables the Defense Logistics Agency to issue firm fixed-price delivery orders for recurring medical supply needs at military healthcare facilities worldwide. The company's established performance on numerous prior delivery orders demonstrates its capacity to fulfill the specialized pharmaceutical requirements of the federal military medical system, including immunosuppressants and biologic agents such as Stelara.
Quick answers
Who was awarded contract SPE2DR26FRRM9?
SPE2DR26FRRM9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FRRM9 worth?
The government has obligated $20,598 on SPE2DR26FRRM9.
Is contract SPE2DR26FRRM9 an order under another contract?
Yes. SPE2DR26FRRM9 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRM9 competed?
The extent of competition for SPE2DR26FRRM9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award